Lindi Jiang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/60048/publications.pdf

Version: 2024-02-01

91 papers	1,565 citations	393982 19 h-index	377514 34 g-index
98 all docs	98 docs citations	98 times ranked	2161 citing authors

#	Article	IF	Citations
1	Targeted therapy of SMMC-7721 liver cancer in vitro and in vivo with carbon nanotubes based drug delivery system. Journal of Colloid and Interface Science, 2012, 365, 143-149.	5.0	179
2	The E3 ubiquitin ligase RNF185 facilitates the cGAS-mediated innate immune response. PLoS Pathogens, 2017, 13, e1006264.	2.1	121
3	The hepatotoxicity of multi-walled carbon nanotubes in mice. Nanotechnology, 2009, 20, 445101.	1.3	89
4	Evaluation of Takayasu arteritis activity by delayed contrast-enhanced magnetic resonance imaging. International Journal of Cardiology, 2012, 155, 262-267.	0.8	75
5	Deletion of BACH1 Attenuates Atherosclerosis by Reducing Endothelial Inflammation. Circulation Research, 2022, 130, 1038-1055.	2.0	55
6	The E3 Deubiquitinase USP17 Is a Positive Regulator of Retinoic Acid-related Orphan Nuclear Receptor Î³t (RORÎ³t) in Th17 Cells. Journal of Biological Chemistry, 2014, 289, 25546-25555.	1.6	54
7	MMP-9 and IL-6 are potential biomarkers for disease activity in Takayasu's arteritis. International Journal of Cardiology, 2012, 156, 236-238.	0.8	43
8	A preliminary study of the oral microbiota in Chinese patients with SjÃ¶grenâ€™s syndrome. Archives of Oral Biology, 2016, 70, 143-148.	0.8	37
9	Cyclophosphamide could be a better choice than methotrexate as induction treatment for patients with more severe Takayasuâ€™s arteritis. Rheumatology International, 2017, 37, 2019-2026.	1.5	31
10	Treatment efficacy and safety of tofacitinib versus methotrexate in Takayasu arteritis: a prospective observational study. Annals of the Rheumatic Diseases, 2022, 81, 117-123.	0.5	31
11	Value of contrast-enhanced ultrasonography of the carotid artery for evaluating disease activity in Takayasu arteritis. Arthritis Research and Therapy, 2019, 21, 24.	1.6	29
12	Value of whole-body contrast-enhanced magnetic resonance angiography with vessel wall imaging in quantitative assessment of disease activity and follow-up examination in Takayasuâ€™s arteritis. Clinical Rheumatology, 2016, 35, 685-693.	1.0	28
13	Identification of susceptibility loci for Takayasu arteritis through a large multi-ancestral genome-wide association study. American Journal of Human Genetics, 2021, 108, 84-99.	2.6	26
14	Clinical patterns and characteristics of ankylosing spondylitis in China. Clinical Rheumatology, 2017, 36, 1561-1568.	1.0	25
15	Treatment of Takayasu arteritis with the IL-6R antibody tocilizumab vs. cyclophosphamide. International Journal of Cardiology, 2018, 266, 222-228.	0.8	25
16	Evaluation of Clinical Measures and Different Criteria for Diagnosis of Adult-onset Stillâ€™s Disease in a Chinese Population. Journal of Rheumatology, 2011, 38, 741-746.	1.0	24
17	Autophagy promotes aortic adventitial fibrosis via the IL-6/Jak1 signaling pathway in Takayasu's arteritis. Journal of Autoimmunity, 2019, 99, 39-47.	3.0	23
18	Features of urate deposition in patients with gouty arthritis of the foot using dualâ€energy computed tomography. International Journal of Rheumatic Diseases, 2015, 18, 560-567.	0.9	22

#	Article	IF	Citations
19	Serum uric acid and its relationship with cardiovascular risk profile in Chinese patients with early-onset coronary artery disease. Clinical Rheumatology, 2015, 34, 1605-1611.	1.0	22
20	Chinese Systemic Lupus Erythematosus Treatment and Research Group Registry VI: Effect of Cigarette Smoking on the Clinical Phenotype of Chinese Patients with Systemic Lupus Erythematosus. PLoS ONE, 2015, 10, e0134451.	1.1	21
21	Remission assessment of rheumatoid arthritis in daily practice in China: a cross-sectional observational study. Clinical Rheumatology, 2018, 37, 597-605.	1.0	21
22	Comparison of the Efficacy and Safety of Adalimumab (Humira) and the Adalimumab Biosimilar Candidate (HS016) in Chinese Patients with Active Ankylosing Spondylitis: A Multicenter, Randomized, Double-Blind, Parallel, Phase III Clinical Trial. BioDrugs, 2020, 34, 381-393.	2.2	21
23	Efficacy and safety of leflunomide treatment in Takayasu arteritis: Case series from the East China cohort. Seminars in Arthritis and Rheumatism, 2020, 50, 59-65.	1.6	19
24	Tofacitinib for the treatment of antineutrophil cytoplasm antibody-associated vasculitis: a pilot study. Annals of the Rheumatic Diseases, 2021, 80, 1631-1633.	0.5	19
25	Influence of urate-lowering therapies on renal handling of uric acid. Clinical Rheumatology, 2016, 35, 133-141.	1.0	18
26	18F-FDG-PET/CT: an accurate method to assess the activity of Takayasuâ€™s arteritis. Clinical Rheumatology, 2018, 37, 1927-1935.	1.0	18
27	Involvement of the pulmonary arteries in patients with Takayasu arteritis: a prospective study from a single centre in China. Arthritis Research and Therapy, 2020, 22, 131.	1.6	18
28	Tofacitinib for treatment in immune-mediated myocarditis: The first reported cases. Journal of Oncology Pharmacy Practice, 2021, 27, 739-746.	0.5	18
29	Efficacy and safety of a selective URAT1 inhibitor SHR4640 in Chinese subjects with hyperuricaemia: a randomized controlled phase II study. Rheumatology, 2021, 60, 5089-5097.	0.9	18
30	Clinical features and current treatments of adult-onset Still's disease: a multicentre survey of 517 patients in China. Clinical and Experimental Rheumatology, 2019, 37 Suppl 121, 52-57.	0.4	18
31	Dualâ€energy computed tomography for monitoring the effect of urateâ€lowering therapy in gouty arthritis. International Journal of Rheumatic Diseases, 2015, 18, 880-885.	0.9	17
32	Chinese Systemic Lupus Erythematosus Treatment and Research Group Registry IX. Chinese Medical Journal, 2017, 130, 1276-1282.	0.9	17
33	In vitro IL-6/IL-6R Trans-Signaling in Fibroblasts Releases Cytokines That May Be Linked to the Pathogenesis of IgG4-Related Disease. Frontiers in Immunology, 2020, 11, 1272.	2.2	17
34	Potential Role of Macrophage Phenotypes and CCL2 in the Pathogenesis of Takayasu Arteritis. Frontiers in Immunology, 2021, 12, 646516.	2.2	16
35	The effects of dopamine receptor 2 expression on B cells on bone metabolism and TNF-Î± levels in rheumatoid arthritis. BMC Musculoskeletal Disorders, 2016, 17, 352.	0.8	15
36	Effectiveness and safety of methotrexate versus leflunomide in 12-month treatment for Takayasu arteritis. Therapeutic Advances in Chronic Disease, 2020, 11, 204062232097523.	1.1	14

#	Article	IF	Citations
37	Serum complement 3 is a potential biomarker for assessing disease activity in Takayasu arteritis. Arthritis Research and Therapy, 2021, 23, 63.	1.6	14
38	A novel model to assess disease activity in Takayasu arteritis based on 18F-FDG-PET/CT: a Chinese cohort study. Rheumatology, 2022, 61, SI14-SI22.	0.9	14
39	Assessment of subclinical left ventricular changes in essential hypertensive patients with hyperuricemia: A three-dimensional speckle-tracking echocardiography study. Clinical and Experimental Hypertension, 2017, 39, 93-99.	0.5	13
40	New urate depositions on dual-energy computed tomography in gouty arthritis during urate-lowering therapy. Rheumatology International, 2017, 37, 1365-1372.	1.5	12
41	YKL-40 as a new biomarker of disease activity in Takayasu arteritis. International Journal of Cardiology, 2019, 293, 231-237.	0.8	12
42	Prognostic factors in IgG4-related disease: a long-term monocentric Chinese cohort study. Clinical Rheumatology, 2021, 40, 2293-2300.	1.0	12
43	Effectiveness and safety of tocilizumab in patients with refractory or severe Takayasu's arteritis: A prospective cohort study in a Chinese population. Joint Bone Spine, 2021, 88, 105186.	0.8	12
44	Hypoparathyroidism in a patient with systemic lupus erythematosus coexisted with ankylosing spondylitis: A case report and review of literature. Joint Bone Spine, 2010, 77, 608-610.	0.8	11
45	Smoking quantity determines disease activity and function in Chinese patients with ankylosing spondylitis. Clinical Rheumatology, 2018, 37, 1605-1616.	1.0	11
46	Comparison of bi-exponential and mono-exponential models of diffusion-weighted imaging for detecting active sacroiliitis in ankylosing spondylitis. Acta Radiologica, 2018, 59, 468-477.	0.5	11
47	Radiology and biomarkers in assessing disease activity in Takayasu arteritis. International Journal of Rheumatic Diseases, 2019, 22, 53-59.	0.9	11
48	Efficacy and safety of tofacitinib versus leflunomide with glucocorticoids treatment in Takayasu arteritis: A prospective study. Seminars in Arthritis and Rheumatism, 2022, 55, 152018.	1.6	11
49	Effectiveness and safety of leflunomide compared with cyclophosphamide as induction therapy in Takayasuâ€™s arteritis: an observational study. Therapeutic Advances in Chronic Disease, 2020, 11, 204062232092201.	1.1	10
50	Advancements in medical and surgical treatments of Takayasu arteritis-induced renal arteritis: a systematic review. Chinese Medical Journal, 2020, 133, 975-981.	0.9	10
51	Epidemiology of Takayasu arteritis in Shanghai: A hospitalâ€based study and systematic review. International Journal of Rheumatic Diseases, 2021, 24, 1247-1256.	0.9	10
52	A comprehensive profile of chemokines in the peripheral blood and vascular tissue of patients with Takayasu arteritis. Arthritis Research and Therapy, 2022, 24, 49.	1.6	10
53	Value of three-dimensional speckle tracking echocardiography to assess left ventricular function in hyperuricemia patients. Clinical Rheumatology, 2018, 37, 2539-2545.	1.0	9
54	The value of interleukin-6 in predicting disease relapse for Takayasu arteritis during 2-year follow-up. Clinical Rheumatology, 2020, 39, 3417-3425.	1.0	9

#	Article	IF	Citations
55	Efficacy and safety of leflunomide versus cyclophosphamide for initial-onset Takayasu arteritis: a prospective cohort study. Therapeutic Advances in Musculoskeletal Disease, 2020, 12, 1759720X2093011.	1.2	9
56	FABP3 overexpression promotes vascular fibrosis in Takayasuâ€™s arteritis by enhancing fatty acid oxidation in aorta adventitial fibroblasts. Rheumatology, 2022, 61, 3071-3081.	0.9	9
57	Clinical and pathological predictors of relapse in IgG4-related disease. Arthritis Research and Therapy, 2022, 24, 106.	1.6	9
58	A randomized, controlled trial of efficacy and safety of Anbainuo, a bio-similar etanercept, for moderate to severe rheumatoid arthritis inadequately responding to methotrexate. Clinical Rheumatology, 2016, 35, 2175-2183.	1.0	8
59	Characteristics and Medium-term Outcomes of Takayasu Arteritisâ€“related Renal Artery Stenosis: Analysis of a Large Chinese Cohort. Journal of Rheumatology, 2021, 48, 87-93.	1.0	8
60	Single-Cell Analysis Identify Transcription Factor BACH1 as a Master Regulator Gene in Vascular Cells During Aging. Frontiers in Cell and Developmental Biology, 2021, 9, 786496.	1.8	8
61	Bile Acids Elevated in Chronic Periaortitis Could Activate Farnesoid-X-Receptor to Suppress IL-6 Production by Macrophages. Frontiers in Immunology, 2021, 12, 632864.	2.2	7
62	Analysis of predictive factors for treatment resistance and disease relapse in Takayasuâ€™s arteritis. Clinical Rheumatology, 2018, 37, 2789-2795.	1.0	6
63	A Randomized, Double-Blind, Non-Inferiority Study of Febuxostat Versus Allopurinol in Hyperuricemic Chinese Subjects With or Without Gout. Rheumatology and Therapy, 2019, 6, 543-557.	1.1	6
64	Serum leptin, a potential predictor of longâ€term angiographic progression in Takayasuâ€™s arteritis. International Journal of Rheumatic Diseases, 2019, 22, 2134-2142.	0.9	5
65	Rapid Onset of Efficacy of Baricitinib in Chinese Patients with Moderate to Severe Rheumatoid Arthritis: Results from Study RA-BALANCE. Advances in Therapy, 2021, 38, 772-781.	1.3	5
66	Improved clinical outcomes of tocilizumab versus cyclophosphamide for IgG4-related disease: insights from a prospective IgG4-related disease registry. Therapeutic Advances in Chronic Disease, 2021, 12, 204062232110287.	1.1	4
67	Effect of hydroxychloroquine on angiographic progression in routine treatment of Takayasu arteritis. Modern Rheumatology, 2021, 31, 1135-1141.	0.9	4
68	Clinical characteristics, imaging phenotypes and events free survival in Takayasu arteritis patients with hypertension. Arthritis Research and Therapy, 2021, 23, 196.	1.6	4
69	Safety and Efficacy of Prefilled Liquid Etanercept-Biosimilar Yisaipu for Active Ankylosing Spondylitis: A Multi-Center Phase III Trial. Rheumatology and Therapy, 2021, 8, 361-374.	1.1	3
70	Curcumin alleviates inflammation in Takayasu's arteritis by blocking CCL2 overexpression in adventitial fibroblasts. Clinical and Experimental Rheumatology, 2021, 39, 161-170.	0.4	3
71	Effectiveness of benzbromarone versus febuxostat in gouty patients: a retrospective study. Clinical Rheumatology, 2022, 41, 2121-2128.	1.0	3
72	High melatonin levels are related to spinal ossification in patients with ankylosing spondylitis. Modern Rheumatology, 2020, 30, 373-378.	0.9	2

#	Article	IF	Citations
73	Changes in Efficacy Indicators for Adalimumab Biosimilar Candidate (HS016) for the Treatment of Active Ankylosing Spondylitis at Various Time Points. Frontiers in Pharmacology, 2020, 11, 606497.	1.6	2
74	Risk assessment model for heart failure in Chinese patients with Takayasuâ€™s arteritis. Clinical Rheumatology, 2021, 40, 4117-4126.	1.0	2
75	Development and validation of a prediction model for glucocorticoid-associated osteonecrosis of the femoral head by targeted sequencing. Rheumatology, 2022, 61, 846-855.	0.9	2
76	Evaluation of adalimumab biosimilar candidate (HS016) in Chinese patients with active ankylosing spondylitis based on a health survey: sub-analysis of a phase 3 study. Clinical Rheumatology, 2022, 41, 731-739.	1.0	2
77	The potential role of leflunomide in inhibiting vascular fibrosis by down-regulating type-II macrophages in Takayasu's arteritis. Clinical and Experimental Rheumatology, 2020, 38 Suppl 124, 69-78.	0.4	2
78	CYR61/TGF-Î² axis promotes adventitial fibrosis of Takayasu's arteritis in the IL-17 mediated inflammatory microenvironment. Clinical and Experimental Rheumatology, 2020, 38, 1102-1111.	0.4	2
79	100.â€ƒEXPLORE THE DIAGNOSTIC CRITERIA FOR TAKAYASU ARTERITIS. Rheumatology, 2019, 58, .	0.9	1
80	The value of ultrasonography combined with clinical features for predicting carotid imaging progression of Takayasu's arteritis: a prospective cohort study. Clinical and Experimental Rheumatology, 2021, 39, 101-106.	0.4	1
81	Carotid Intima-media Thickness/Diameter Ratio and Peak Systolic Velocity as Risk Factors for Neurological Severe Ischemic Events in Takayasu Arteritis. Journal of Rheumatology, 2022, 49, 482-488.	1.0	1
82	161.â€ƒAUGMENTED IL-6 IMPLIES UN-SEVERE VASCULAR STENOSIS IN TAKAYASUâ€™S ARTERITIS: A CROSS-SECTIONAL STUDY BASED ON ECTA COHORT. Rheumatology, 2019, 58, .	0.9	0
83	341.â€ƒLONG-TERM CLINICAL AND SURGICAL OUTCOMES OF TAKAYASU ARTERITIS PATIENTS WITH AORTITIS: CASE SERIES FROM THE EAST CHINA COHORT. Rheumatology, 2019, 58, .	0.9	0
84	342.â€ƒLONG-TERM EFFICACY AND SAFETY OF LEFLUNOMIDE TREATMENT IN TAKAYASU ARTERITIS: CASE SERIES FROM THE EAST CHINA COHORT. Rheumatology, 2019, 58, .	0.9	0
85	149.â€ƒPULMONARY PRESENTATIONS IN TAKAYASU ARTERITIS. Rheumatology, 2019, 58, .	0.9	0
86	199.â€ƒM1-TO-M2 PHENOTYPE SHIFT OF MACROPHAGES IN VASCULAR TISSUE OF TAKAYASU ARTERITIS. Rheumatology, 2019, 58, .	0.9	0
87	Immunosuppression medication and cardiac function improvement treatments might prevent Takayasu arteritis patients with aortitis from receiving cardiac surgery. Chinese Medical Journal, 2021, 134, 625-627.	0.9	0
88	Potential risk of hyperuricemia: leading cardiomyocyte hypertrophy by inducing autophagy. American Journal of Translational Research (discontinued), 2020, 12, 1894-1903.	0.0	0
89	The value of ultrasonography combined with clinical features for predicting carotid imaging progression of Takayasu's arteritis: a prospective cohort study. Clinical and Experimental Rheumatology, 2021, 39 Suppl 129, 101-106.	0.4	0
90	Curcumin alleviates inflammation in Takayasu's arteritis by blocking CCL2 overexpression in adventitial fibroblasts. Clinical and Experimental Rheumatology, 2021, 39 Suppl 129, 161-170.	0.4	0

#	Article	IF	Citations
91	Eosinophilic granulomatosis with polyangiitis is associated with hepatitis B virus infection. Clinical Rheumatology, 2022, , .	1.0	0